Moomoo AI 已提取核心信息
Alon Ben-Noon, an Israeli citizen, has filed an amendment to Schedule 13G/A with the United States Securities and Exchange Commission, indicating a significant ownership stake in NeuroSense Therapeutics Ltd. As of December 31, 2023, Ben-Noon beneficially owns 3,072,600 ordinary shares of NeuroSense Therapeutics, which represents 19.98% of the company's class of securities. This stake includes 36,000 restricted share units that vested during the year. The filing, dated February 13, 2024, confirms that the information provided is true and complete to the best of Ben-Noon's knowledge after reasonable inquiry.
Alon Ben-Noon, an Israeli citizen, has filed an amendment to Schedule 13G/A with the United States Securities and Exchange Commission, indicating a significant ownership stake in NeuroSense Therapeutics Ltd. As of December 31, 2023, Ben-Noon beneficially owns 3,072,600 ordinary shares of NeuroSense Therapeutics, which represents 19.98% of the company's class of securities. This stake includes 36,000 restricted share units that vested during the year. The filing, dated February 13, 2024, confirms that the information provided is true and complete to the best of Ben-Noon's knowledge after reasonable inquiry.
以色列公民阿隆·本·努恩已向美国证券交易委员会提交了附表13G/A的修正案，表示拥有NeuroSense Therapeutics Ltd的大量所有权。截至2023年12月31日，Ben-Noon实益拥有NeuroSense Therapeutics的3,072,600股普通股，占该公司证券类别的19.98％。该股份包括年内归属的36,000股限制性股票单位。这份日期为2024年2月13日的文件证实，经过合理的调查，据本·努恩所知，所提供的信息是真实和完整的。
以色列公民阿隆·本·努恩已向美国证券交易委员会提交了附表13G/A的修正案，表示拥有NeuroSense Therapeutics Ltd的大量所有权。截至2023年12月31日，Ben-Noon实益拥有NeuroSense Therapeutics的3,072,600股普通股，占该公司证券类别的19.98％。该股份包括年内归属的36,000股限制性股票单位。这份日期为2024年2月13日的文件证实，经过合理的调查，据本·努恩所知，所提供的信息是真实和完整的。
有用
没用
